A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
We report the first genome-wide association study (GWAS) whose sample size (1,053 Swedish subjects) is sufficiently powered to detect genome-wide significance (p<1.5 x 10(-7)) for polymorphisms that modestly alter therapeutic warfarin dose. The anticoagulant drug warfarin is widely prescribed for...
Main Authors: | Fumihiko Takeuchi, Ralph McGinnis, Stephane Bourgeois, Chris Barnes, Niclas Eriksson, Nicole Soranzo, Pamela Whittaker, Venkatesh Ranganath, Vasudev Kumanduri, William McLaren, Lennart Holm, Jonatan Lindh, Anders Rane, Mia Wadelius, Panos Deloukas |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2009-03-01
|
Series: | PLoS Genetics |
Online Access: | http://europepmc.org/articles/PMC2652833?pdf=render |
Similar Items
-
Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population
by: Jia LQ, et al.
Published: (2017-03-01) -
Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy
by: Behzad Poopak, et al.
Published: (2016-02-01) -
PK/PD of warfarin associated with genetic polymorphisms of VKORC1 and CYP2C9 in indonesian patients
by: Taofik Rusdiana, et al.
Published: (2012-01-01) -
VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients
by: Sea Mi Park, et al.
Published: (2013-05-01) -
Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction
by: Seljeflot Ingebjørg, et al.
Published: (2008-06-01)